These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: IL-1 beta, IL-1 receptor antagonist and soluble type II IL-1 receptor in synovial fluid of patients with temporomandibular disorders.
    Author: Tominaga K, Habu M, Sukedai M, Hirota Y, Takahashi T, Fukuda J.
    Journal: Arch Oral Biol; 2004 Jun; 49(6):493-9. PubMed ID: 15099807.
    Abstract:
    Among the members of the interleukin-1 (IL-1) family, IL-1 beta, which is a major agonist, has been detected in synovial fluid (SF) of the temporomandibular joint (TMJ) of patients with temporomandibular joint disorders (TMD). However, there is little knowledge regarding suppressive molecules, such as IL-1 receptor antagonist (IL-1ra) and the soluble form of type II IL-1 receptor (sIL-1RII), in TMD patients. The aim of this study was to investigate the levels of IL-1 beta, IL-1ra and sIL-1RII in the TMJ SF of patients with TMD and their relationship. Fifty-two SF samples from TMD patients and nine samples from asymptomatic volunteers were examined. Detected levels of IL-1 beta and sIL-1RII were significantly higher in the TMD group compared with the volunteer group. There was no significant difference in IL-1ra levels between the TMD and volunteer groups. The IL-1 beta/IL-1ra ratio in the TMD group, however, was higher than that in the volunteer group. In the TMD group, positive correlations were found between IL-1 beta and IL-1ra, IL-1ra and sIL-1RII, and IL-1 beta and sIL-1RII. In addition to increased IL-1 beta, development of TMD may also lead to decreased IL-1ra and increased sIL-1RII in response to increasing IL-1.
    [Abstract] [Full Text] [Related] [New Search]